Trials and tribulations of highly effective modulator therapies in cystic fibrosis

Elborn, 2016, Cystic fibrosis, Lancet, 388, 2519, 10.1016/S0140-6736(16)00576-6 O'Sullivan, 2009, Cystic fibrosis, Lancet, 373, 1891, 10.1016/S0140-6736(09)60327-5 Jih, 2013, Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle, PNAS, 110, 4404, 10.1073/pnas.1215982110 Davies, 2016, Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study, Lancet Respir Med, 4, 107, 10.1016/S2213-2600(15)00545-7 Davies, 2013, Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation, Am J Respir Crit Care Med, 187, 1219, 10.1164/rccm.201301-0153OC Davies, 2021, Ivacaftor in infants aged 4 to <12 months with cystic fibrosis and a gating mutation. results of a two-part phase 3 clinical trial, Am J Respir Crit Care Med, 203, 585, 10.1164/rccm.202008-3177OC McKone, 2014, Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST), Lancet Respir Med, 2, 902, 10.1016/S2213-2600(14)70218-8 Ramsey, 2011, A CFTR potentiator in patients with cystic fibrosis and the G551D mutation, N Engl J Med, 365, 1663, 10.1056/NEJMoa1105185 Rosenfeld, 2019, An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2–5 years (KLIMB), J Cyst Fibros, 18, 838, 10.1016/j.jcf.2019.03.009 Rosenfeld, 2018, Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study, Lancet Respir Med, 6, 545, 10.1016/S2213-2600(18)30202-9 Davies, 2013, Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial, Lancet Respir Med, 1, 630, 10.1016/S2213-2600(13)70182-6 Kane, 2016, Lung clearance index response in patients with CF with class III CFTR mutations, Thorax, 71, 476, 10.1136/thoraxjnl-2015-207894 Connett, 2019, Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy, Drug Des Devel Ther, 13, 2405, 10.2147/DDDT.S153719 Wainwright, 2015, Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR, N Engl J Med, 373, 220, 10.1056/NEJMoa1409547 Rowe, 2017, Lumacaftor/ivacaftor treatment of patients with cystic fibrosis heterozygous for F508del-CFTR, Ann Am Thorac Soc, 14, 213, 10.1513/AnnalsATS.201609-689OC McNamara, 2019, Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study, Lancet Respir Med, 7, 325, 10.1016/S2213-2600(18)30460-0 Rayment, 2022, A phase 3, open-label study of lumacaftor/ivacaftor in children 1 to less than 2 years of age with cystic fibrosis homozygous for F508del-CFTR, Am J Respir Crit Care Med, 206, 1239, 10.1164/rccm.202204-0734OC Ratjen, 2017, Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial, Lancet Respir Med, 5, 557, 10.1016/S2213-2600(17)30215-1 Sergeev, 2020, Safety and effectiveness of lumacaftor-ivacaftor in adults with cystic fibrosis: A single-center Canadian experience, Can J Respir, Crit Care, Sleep Med, 4, 174 Dagenais, 2021, Real-world safety of CFTR modulators in the treatment of cystic fibrosis: A systematic review, J Clin Med, 10, 23, 10.3390/jcm10010023 Nash, 2020, Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators – an international survey, J Cyst Fibros, 19, 521, 10.1016/j.jcf.2020.02.018 Popowicz, 2017, Immediate effects of lumacaftor/ivacaftor administration on lung function in patients with severe cystic fibrosis lung disease, J Cyst Fibros, 16, 392, 10.1016/j.jcf.2017.02.009 Finnegan, 2020, Evidence of small airways disease and the immediate effects of lumacaftor/ivacaftor in children with cystic fibrosis, Ir Med J, 113, 1 Burgel, 2020, Real-life safety and effectiveness of lumacaftor-ivacaftor in patients with cystic fibrosis, Am J Respir Crit Care Med, 201, 188, 10.1164/rccm.201906-1227OC Choong, 2022, Therapeutic drug monitoring of ivacaftor, lumacaftor, tezacaftor, and elexacaftor in cystic fibrosis: where are we now?, Pharmaceutics, 14, 1674, 10.3390/pharmaceutics14081674 Davies, 2021, J Cyst Fibros, 20, 68, 10.1016/j.jcf.2020.07.023 Rowe, 2017, Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis, N Engl J Med, 377, 2024, 10.1056/NEJMoa1709847 Taylor-Cousar, 2017, Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del, N Engl J Med, 377, 2013, 10.1056/NEJMoa1709846 (TGA), T.G.A. Trikaftor. 2021 [cited 2023 May]; Available from: https://www.tga.gov.au/resources/auspmd/trikafta. Heijerman, 2019, Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial, Lancet, 394, 1940, 10.1016/S0140-6736(19)32597-8 Sutharsan, 2022, Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial, Lancet Respir Med, 10, 267, 10.1016/S2213-2600(21)00454-9 Nichols, 2022, Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: a clinical trial, Am J Respir Crit Care Med, 205, 529, 10.1164/rccm.202108-1986OC Mall, 2022, Efficacy and safety of elexacaftor/tezacaftor/ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for f508del and a minimal function mutation: a phase 3B, randomized, placebo-controlled study, Am J Respir Crit Care Med, 206, 1361, 10.1164/rccm.202202-0392OC Zemanick, 2021, A phase 3 open-label study of elexacaftor/tezacaftor/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele, Am J Respir Crit Care Med, 203, 1522, 10.1164/rccm.202102-0509OC Goralski, 2023, Phase 3 open-label clinical trial of elexacaftor/tezacaftor/ivacaftor in children aged 2–5 years with cystic fibrosis and at least one F508del allele, Am J Respir Crit Care Med, 208, 59, 10.1164/rccm.202301-0084OC Middleton, 2019, Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele, N Engl J Med, 381, 1809, 10.1056/NEJMoa1908639 Davies, 2018, VX-659–tezacaftor–ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles, N Engl J Med, 379, 1599, 10.1056/NEJMoa1807119 Ramsey, 2022, Cystic fibrosis patients on cystic fibrosis transmembrane conductance regulator modulators have a reduced incidence of cirrhosis, World J Hepatol, 14, 411, 10.4254/wjh.v14.i2.411 Rowe, 2014, Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis, Am J Respir Crit Care Med, 190, 175, 10.1164/rccm.201404-0703OC Taylor-Cousar, 2016, Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States, J Cyst Fibros, 15, 116, 10.1016/j.jcf.2015.01.008 Taylor-Cousar, 2020, Impact on fertility, pregnancy, and lactation in women with cystic fibrosis, J Clin Med, 9, 10.3390/jcm9092706 Frost, 2019, Ivacaftor is associated with reduced lung infection by key cystic fibrosis pathogens. A cohort study using national registry data, Ann Am Thorac Soc, 16, 1375, 10.1513/AnnalsATS.201902-122OC Wiesel, 2023, Eradication of nontuberculous mycobacteria in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor: a multicenter cohort study, J Cyst Fibros, 10.1016/j.jcf.2023.05.003 Stallings, 2018, Energy balance and mechanisms of weight gain with ivacaftor treatment of cystic fibrosis gating mutations, J Pediatr, 201, 229, 10.1016/j.jpeds.2018.05.018 Leonard, A., et al., Nutritional considerations for a new era: A CF foundation position paper. J Cystic Fibrosis. Bailey, 2021, Effect of CFTR modulators on anthropometric parameters in individuals with cystic fibrosis: an evidence analysis center systematic review, J Acad Nutr Diet, 121, 1364, 10.1016/j.jand.2020.03.014 Caley, 2023, Body mass index and nutritional intake following Elexacaftor/Tezacaftor/Ivacaftor modulator therapy in adults with cystic fibrosis, J Cyst Fibros, 10.1016/j.jcf.2023.06.010 King, 2021, Nutrition, 85, 10.1016/j.nut.2020.111124 Petersen, 2022, Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis, J Cyst Fibros, 21, 265, 10.1016/j.jcf.2021.11.012 Yuzyuk, 2023, Improvement of lipid and lipoprotein profiles in children and adolescents with cystic fibrosis on CFTR modulator therapy, J Cyst Fibros, 10.1016/j.jcf.2023.07.001 Wilschanski, 1998, Pathology of pancreatic and intestinal disorders in cystic fibrosis, J R Soc Med, 91, 40, 10.1177/014107689809134S07 Gibson-Corley, 2016, Pancreatic pathophysiology in cystic fibrosis, J Pathol, 238, 311, 10.1002/path.4634 Sergeev, 2020, The extrapulmonary effects of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis, Ann Am Thorac Soc, 17, 147, 10.1513/AnnalsATS.201909-671CME Sadras, 2023, Acute pancreatitis in pancreatic-insufficient cystic fibrosis patients treated with CFTR modulators, J Cyst Fibros, 22, 777, 10.1016/j.jcf.2023.02.013 Gould, 2022, CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis, J Cyst Fibros, 21, 600, 10.1016/j.jcf.2021.09.010 Megalaa, 2019, Time for a gut check: pancreatic sufficiency resulting from CFTR modulator use, Pediatr Pulmonol, 54, 10.1002/ppul.24353 Petrocheilou, 2020, Pancreatitis in a patient with cystic fibrosis taking ivacaftor, Children (Basel), 7, 6 Francalanci, M., et al., Nutritional status and circulating levels of fat-soluble vitamins in cystic fibrosis patients: a cohort study and evaluation of the Effect of CFTR Modulators. Children (Basel), 2023. 10(2). Sommerburg, 2021, CFTR modulator therapy with lumacaftor/ivacaftor alters plasma concentrations of lipid-soluble vitamins A and E in patients with cystic fibrosis, Antioxidants (Basel), 10, 483, 10.3390/antiox10030483 Gelzo, 2021, Lumacaftor/ivacaftor improves liver cholesterol metabolism but does not influence hypocholesterolemia in patients with cystic fibrosis, J Cyst Fibros, 20, e1, 10.1016/j.jcf.2020.06.015 Hergenroeder, 2023, The impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis, J Cyst Fibros, 10.1016/j.jcf.2023.08.002 Wisniewski, 2022, Hypervitaminosis A with fulminant secondary intracranial hypertension following personalized medicine-based Elexacaftor/Tezacaftor/Ivacaftor initiation in a preadolescent with cystic fibrosis, J Cyst Fibros, 21, e217, 10.1016/j.jcf.2022.01.010 Miller, 2022, Papilledema and hypervitaminosis A after elexacaftor/tezacaftor/ivacaftor for cystic fibrosis, Can J Ophthalmol, 57, e6, 10.1016/j.jcjo.2021.04.018 Christian, F., et al., Sustained glycemic control with ivacaftor in cystic fibrosis–related diabetes. J Invest Med High Impact Case Rep, 2019. 7: p. 2324709619842898. Bellin, 2013, Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study, Pediatr Diabetes, 14, 417, 10.1111/pedi.12026 Hayes, 2014, Resolution of cystic fibrosis-related diabetes with ivacaftor therapy, Am J Respir Crit Care Med, 190, 590, 10.1164/rccm.201405-0882LE Kelly, 2019, Islet hormone and incretin secretion in cystic fibrosis after four months of ivacaftor therapy, Am J Respir Crit Care Med, 199, 342, 10.1164/rccm.201806-1018OC Li, 2019, Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor, J Cyst Fibros, 18, 144, 10.1016/j.jcf.2018.07.010 Thomassen, 2018, Effect of Lumacaftor/Ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients, J Cyst Fibros, 17, 271, 10.1016/j.jcf.2017.11.016 Scully, 2022, The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis, J Cyst Fibros, 21, 258, 10.1016/j.jcf.2021.09.001 Chan, 2022, Glycemia and β-cell function before and after elexacaftor/tezacaftor/ivacaftor in youth and adults with cystic fibrosis, J Clin Transl Endocrinol, 30 Piona, 2022, Impact of CFTR modulators on beta-cell function in children and young adults with cystic fibrosis, J Clin Med, 11, 4149, 10.3390/jcm11144149 Korten, 2022, Short-term effects of elexacaftor/tezacaftor/ivacaftor combination on glucose tolerance in young people with cystic fibrosis—an observational pilot study., Front Pediatr, 10, 10.3389/fped.2022.852551 Lanng, 1995, Glucose tolerance in patients with cystic fibrosis: five year prospective study, BMJ, 311, 655, 10.1136/bmj.311.7006.655 Lahiri, 2022, Recent advances in the early treatment of cystic fibrosis: bridging the gap to highly effective modulator therapy, Pediatr Pulmonol, 57, S60, 10.1002/ppul.25660 Gelfond, 2017, Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation, Clin Transl Gastroenterol, 8, e81, 10.1038/ctg.2017.10 Ooi, 2018, Impact of CFTR modulation with ivacaftor on gut microbiota and intestinal inflammation, Sci Rep, 8, 10.1038/s41598-018-36364-6 Tétard, 2020, Reduced intestinal inflammation with lumacaftor/ivacaftor in adolescents with cystic fibrosis, J Pediatr Gastroenterol Nutr, 71, 778, 10.1097/MPG.0000000000002864 Safe, 2016, Resolution of intestinal histopathology changes in cystic fibrosis after treatment with ivacaftor, Ann Am Thorac Soc, 13, 297, 10.1513/AnnalsATS.201510-669LE Hubert, 2018, Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2years of treatment with ivacaftor in a real-world setting, J Cyst Fibros, 17, 89, 10.1016/j.jcf.2017.07.001 Flass, 2013, Cirrhosis and other liver disease in cystic fibrosis, J Cyst Fibros, 12, 116, 10.1016/j.jcf.2012.11.010 van de Peppel, 2017, Diagnosis, follow-up and treatment of cystic fibrosis-related liver disease, Curr Opin Pulm Med, 23, 562, 10.1097/MCP.0000000000000428 Bessonova, 2018, Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor, Thorax, 73, 731, 10.1136/thoraxjnl-2017-210394 Dempsey, 2019, The effect of modulator therapy on liver function in patients with cystic fibrosis-related liver disease (CFLD), Arch Dis Child, 104, A150 Olivier, 2023, Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis, Front Pharmacol, 14, 10.3389/fphar.2023.1176815 Sermet-Gaudelus, 2016, Bone demineralization is improved by ivacaftor in patients with cystic fibrosis carrying the p.Gly551Asp mutation, J Cyst Fibros, 15, e67, 10.1016/j.jcf.2016.09.003 Edgeworth, 2017, Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment, Clin Sci, 131, 2037, 10.1042/CS20170995 Wark, 2019, Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction, BMC Pulm Med, 19, 10.1186/s12890-019-0866-y Savi, 2019, Effects of Lumacaftor/Ivacaftor on physical activity and exercise tolerance in three adults with cystic fibrosis, J Cyst Fibros, 18, 420, 10.1016/j.jcf.2019.03.001 Philipsen, 2023, WS01.04 Longtime follow-up on exercise capacity and quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/iIvacaftor & #x2013; a Copenhagen cohort, J Cyst Fibros, 22, S2, 10.1016/S1569-1993(23)00190-X Stastna, 2023, P055 No impact of elexacaftor/tezacaftor/ivacaftor (ETI) CFTRm therapy on male infertility due to CBAVD in two adult cystic fibrosis patients: case report, J Cyst Fibros, 22, 10.1016/S1569-1993(23)00430-7 O'Connor, 2021, Elexacafator/tezacaftor/ivacaftor resolves subfertility in females with CF: A two center case series, J Cyst Fibros, 20, 399, 10.1016/j.jcf.2020.12.011 Taylor-Cousar, 2023, The impact of highly effective cystic fibrosis transmembrane conductance regulator modulators on the health of female subjects with cystic fibrosis, Clin Ther, 45, 278, 10.1016/j.clinthera.2023.01.016 Jones, 2015, Potential impact on fertility of new systemic therapies for cystic fibrosis, Paediatr Respir Rev, 16, 25 McKinzie, 2017, Worsening anxiety and depression after initiation of lumacaftor/ivacaftor combination therapy in adolescent females with cystic fibrosis, J Cyst Fibros, 16, 525, 10.1016/j.jcf.2017.05.008 Ramos, 2021, Challenges in the use of highly effective modulator treatment for cystic fibrosis, J Cyst Fibros, 20, 381, 10.1016/j.jcf.2021.01.007 Taylor-Cousar, 2021, Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation, J Cyst Fibros, 20, 402, 10.1016/j.jcf.2021.03.006 Middleton, 2020, ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases, Eur Respir J, 55, 10.1183/13993003.01208-2019 Jain, 2022, Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design., BMJ Open Respir Res, 9 Rotolo, 2020, Testicular pain following initiation of elexacaftor/tezacaftor/ivacaftor in males with cystic fibrosis, J Cyst Fibros, 19, e39, 10.1016/j.jcf.2020.04.017 Heo, 2022, Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy, J Cyst Fibros, 21, 339, 10.1016/j.jcf.2021.10.002 Ibrahim, 2023, Individualized approach to elexacaftor/tezacaftor/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: A case series, Front Pharmacol, 14, 10.3389/fphar.2023.1156621 Zhang, L., et al., Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis. Therapeutic Advances in Respiratory Disease, 2022. 16: p. 17534666221144211. Baroud, 2023, Management of neuropsychiatric symptoms in adults treated with elexacaftor/tezacaftor/ivacaftor, Pediatr Pulmonol, 58, 1920, 10.1002/ppul.26412 Talwalkar, 2017, Cystic fibrosis transmembrane regulator modulators: implications for the management of depression and anxiety in cystic fibrosis, Psychosomatics, 58, 343, 10.1016/j.psym.2017.04.001 Tindell, 2020, Trikafta and psychopathology in cystic fibrosis: A case report, Psychosomatics, 61, 735, 10.1016/j.psym.2020.06.021 Barry, 2021, Triple therapy for cystic fibrosis phe508del–gating and –residual function genotypes, N Engl J Med, 385, 815, 10.1056/NEJMoa2100665 Piehler, 2023, Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis, Front Pharmacol, 14, 10.3389/fphar.2023.1179208 Konstan, 2017, Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study, Lancet Respir Med, 5, 107, 10.1016/S2213-2600(16)30427-1 Gramegna, 2022, Onset of systemic arterial hypertension after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A case series, J Cyst Fibros, 21, 885, 10.1016/j.jcf.2022.04.010 Diseroad, E.R., P.J. Mogayzel, Jr., and A. Pan, Rechallenge of Elexacaftor/Tezacaftor/Ivacaftor After Skin Rash in Two Pediatric Patients. J Pediatr Pharmacol Ther, 2022. 27(5): p. 463-466. Pohl, 2018, Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation, PLoS One, 13, 10.1371/journal.pone.0209026 Roehmel, 2021, Drug allergy to CFTR modulator therapy associated with lumacaftor-specific CD4⁺ T lymphocytes, J Allergy Clin Immunol, 147, 753, 10.1016/j.jaci.2020.05.041 Mederos‐Luis, 2022, Toxic epidermal necrolysis induced by cystic fibrosis transmembrane conductance regulator modulators, Contact Dermatitis, 86, 224, 10.1111/cod.14002 Loukou, 2020, Longitudinal changes in lung function following initiation of lumacaftor/ivacaftor combination, J Cyst Fibros, 19, 534, 10.1016/j.jcf.2019.09.009 Dryden, 2018, The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review, Arch Dis Child, 103, 68, 10.1136/archdischild-2015-310420 Jordan, 2016, Therapeutic challenges posed by critical drug–drug interactions in cystic fibrosis, Pediatr Pulmonol, 51, S61, 10.1002/ppul.23505 Garg, 2019, Pharmacokinetic and drug-drug interaction profiles of the combination of tezacaftor/ivacaftor, Clin Transl Sci, 12, 267, 10.1111/cts.12610 Ince, 2023, Clearing up the smoke: Physical and mental health considerations regarding cannabis use in adolescents with cystic fibrosis, Pediatr Pulmonol, 58, 398, 10.1002/ppul.26241 Scotet, 2020, The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTR gene discovery, Genes (Basel), 11, 589, 10.3390/genes11060589 McBennett, 2022, Increasing life expectancy in cystic fibrosis: advances and challenges, Pediatr Pulmonol, 57, S5 Balfour-Lynn, 2022, CFTR modulator therapies – Effect on life expectancy in people with cystic fibrosis, Paediatr Respir Rev, 42, 3 Lopez, 2023, Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del, J Cyst Fibros, 22, 607, 10.1016/j.jcf.2023.02.004 Stephenson, 2017, The changing epidemiology and demography of cystic fibrosis, Presse Med, 46, e87, 10.1016/j.lpm.2017.04.012 Lee, 2023, Effect of elexacaftor/tezacaftor/ivacaftor on annual rate of lung function decline in people with cystic fibrosis, J Cyst Fibros, 22, 402, 10.1016/j.jcf.2022.12.009 Dilokthornsakul, 2016, Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation, Eur Respir J, 47, 1697, 10.1183/13993003.01444-2015 Dilokthornsakul, 2017, Forecasting the long-term clinical and economic outcomes of lumacaftor/ivacaftor in cystic fibrosis patients with homozygous phe508del mutation, Value Health, 20, 1329, 10.1016/j.jval.2017.06.014 Higgins, 2020, Real-world outcomes among patients with cystic fibrosis treated with ivacaftor: 2012–2016 experience, Pulmonary Therapy, 6, 141, 10.1007/s41030-020-00115-8 Nichols, 2021, PROMISE: working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy, J Cyst Fibros, 20, 205, 10.1016/j.jcf.2021.02.003 Allen, 2023, Future therapies for cystic fibrosis, Nat Commun, 14, 693, 10.1038/s41467-023-36244-2 Taylor-Cousar, 2023, CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis, Lancet, 10.1016/S0140-6736(23)01609-4 ISRCTN14081521. A randomised open-label trial to assess change in respiratory function for people with cystic fibrosis (pwCF) established on triple combination therapy (Kaftrio™) after rationalisation of nebulised mucoactive therapies (the CF STORM trial). 2021; Available from: https://www.isrctn.com/ISRCTN14081521.